Medical Science Liaison, Neurodegeneration; MI, N. IN; excluding Detroit

Medical Science Liaison, Neurodegeneration

Location:

MI, N. IN (excluding Detroit)

The primary role of the Medical Science Liaison (MSL) is to engage in meaningful peer‑to‑peer scientific dialogue with healthcare system leaders such as Regional Thought Leaders (RTLs), National Thought Leaders, and Healthcare Professionals (HCPs) within a defined geography to translate science into patient care. MSLs also engage the top HCPs in high‑disease burden hospitals.

The MSL captures medical insights and acts as a clinical & scientific advisor to cross‑functional partners. The role ensures interactions are aligned with enterprise and medical strategies so that patients have access to BMS medicines through the efforts to keep the medical community fully apprised of their safe and effective use. The MSL works with the medical community to address other pertinent scientific questions related to approved assets and indications.

Engagement with HCPs is focused on pre‑ and peri‑launch activities or according to lifecycle needs of the brand.

The MSL will engage in educational dialogue with relevant HCPs and share clinical evidence in line with physicians’ needs and the field medical plan. The MSL will also be responsible for serving as “Medical on Call,” virtually engaging treating physicians in the community, facilitated by their commercial counterpart, TAS (Therapeutic Area Specialist), to answer unsolicited off‑label and technically complex questions in real time.

The Medical on Call capability and operating model will be implemented in 2024/5 on a market‑by‑market basis as the technology and operating model are ready.

This role is field‑based, and it is anticipated that the employee will spend a majority of the time in the field interacting with external stakeholders, including investigators and clinical thought leaders, while also supporting internal stakeholders and maintaining a high level of therapeutic expertise.

Develop trusted relationships with appropriate academic and community Thought Leaders (TLs) in neurology through high‑quality peer‑to‑peer scientific dialogue in both proactive and reactive settings. The MSL will use various channels for interactions (1:1, group presentations, virtual, etc.).

• Effectively collaborate and engage in scientific dialogue with TLs to gain insights on the clinical landscape to ensure a product/disease‑area focused medical plan that translates into an effective launch.
• Proactively engage in scientific and clinical conversation to ensure a product/disease‑area focused medical plan that translates into an effective launch and lifecycle management activities.
• Engage with medical societies, PAGs (Patient Advocacy Groups), and guideline committee members as appropriate.
• Provide training for external speakers as needed.
• Strategically engage payers in the pre‑ and peri‑launch phases (with fHEOR and Account Executives).
• Provide medical support to address unsolicited HCP questions in real time, both in face‑to‑face interactions and through the Medical on Call virtual capability.
• Develop credible connections with key Thought Leaders (TLs) in neurology through high‑quality peer‑to‑peer scientific dialogue.
• Appropriately document and achieve annual goals.
• Leverage digital capabilities to enhance medical engagement.

• Provide recommendations and insights to the clinical development team on study feasibilities within the therapeutic area based on knowledge of the field and direct contacts with potential investigators.
• Liaise with key large accounts to understand clinical barriers to patient access and ensure equity in access to clinical trials.
• Lead major evidence read‑outs with clinical trial investigators, e.g., Phase 3 top‑line data.
• Support Interventional and Non‑Interventional Research (NIR) studies (e.g., identification and assessment of potential study sites) to facilitate patient recruitment and discussions around the safe and effective use of BMS investigational products.
• Provide recommendations and insights to the clinical development team on study and site feasibilities within the therapeutic area based on knowledge of the…